What the evidence shows: apoC-III therapy dramatically lowers triglycerides and pancreatitis risk
The most direct answer comes from two large, placebo-controlled trials of olezarsen (an antisense oligonucleotide that blocks apoC-III production). In these trials, patients with severe hypertriglyceridemia (very high blood fats) who received olezarsen saw their triglyceride levels drop by about 50–72% more than placebo at 6 months [1]. This is a huge reduction—enough to bring many patients from dangerous levels into a safer range. More importantly, the rate of acute pancreatitis (a painful, potentially fatal inflammation of the pancreas) was about 85% lower in the olezarsen group compared with placebo [1].
A meta-analysis pooling 10 randomized trials of apoC-III inhibitors (including olezarsen, volanesorsen, and plozasiran) found a similar effect: a relative risk reduction of 83% for acute pancreatitis [2]. This consistency across different drugs and studies strengthens the conclusion that lowering apoC-III is a reliable way to prevent this complication. The meta-analysis also showed that these drugs can normalize triglyceride levels in many patients with severe hypertriglyceridemia—about 8 times more likely than placebo [2].
How does it work? By unblocking the enzyme that clears fat from the blood
ApoC-III is a protein that normally inhibits lipoprotein lipase (LPL), the enzyme that breaks down triglyceride-rich particles in the blood. By reducing apoC-III, these therapies 'release the brake' on LPL, allowing it to work more efficiently. A small study in patients with partial lipodystrophy (a condition causing severe hypertriglyceridemia) showed that volanesorsen increased LPL activity by about 70% while cutting triglycerides from a median of 503 mg/dL to 116 mg/dL [4]. This mechanism explains why the effect is so powerful and why it also reduces the number of triglyceride-rich particles, as seen in a study of plozasiran [3].
Cautions and limitations: side effects and unanswered questions
While the benefits are clear, the therapy is not without risks. In the olezarsen trials, the 80-mg dose was associated with more frequent liver enzyme elevations and thrombocytopenia (low platelet count, below 100,000 per microliter), and there was a dose-dependent increase in liver fat [1]. These side effects were less common at the 50-mg dose, which still provided substantial triglyceride reduction. The meta-analysis reported that overall adverse events were similar to placebo, but it did not separate out these specific lab abnormalities [2].
Another caveat is that these studies primarily measured surrogate outcomes (triglyceride levels) and pancreatitis events over a relatively short period (up to 12 months). Long-term safety and whether the reduction in pancreatitis translates to improved survival or quality of life over years remains to be seen. Also, the effect on cardiovascular events is not yet established—one study of plozasiran showed favorable changes in lipoprotein particle size, but no outcomes trial has been completed [3].
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2025, 4 from 2024 or later, 5 in Q1 journals, collectively cited 55 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 29 papers retrieved from a database of over 500 million.
Sources used in this answer
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
In two double-blind, placebo-controlled trials (CORE-TIMI 72a and CORE2-TIMI 72b) involving 1,061 patients with severe hypertriglyceridemia, olezarsen reduced triglycerides by 49–72% more than placebo at 6 months and lowered the rate of acute pancreatitis by 85% (rate ratio 0.15).
Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: a meta-analysis of randomized controlled trials
A meta-analysis of 10 randomized controlled trials (1,204 participants) of apoC-III inhibitors found a 60.6% reduction in triglycerides and a relative risk reduction of 83% for acute pancreatitis, with similar adverse events to placebo.
Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia
In two phase 2 studies (SHASTA-2 and MUIR) of plozasiran, an siRNA targeting apoC-III, triglyceride-rich lipoprotein particles were reduced by about 50%, LDL particles shifted from small to larger sizes, and HDL particles increased modestly.
Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy
In a small randomized, double-blind study of 5 patients with partial lipodystrophy, volanesorsen increased lipoprotein lipase activity by about 70% and reduced triglycerides from a median of 503 to 116 mg/dL, with improvements in insulin sensitivity and liver fat.
Olezarsen and post-prandial triglyceride levels
An editorial highlights that olezarsen also reduces postprandial (after-meal) triglyceride levels, which may be an even better marker of cardiovascular risk than fasting levels, though this effect was not extensively studied in the original trials.